Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Heart Journal

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EHJ.2004.05.029PMID 15342170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism of collagen is altered in hypertensives with increased intima media thickness

  2006cited by this paper
• Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study.

  2005cited by this paper
• Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study

  2004cited by this paper
• Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study.

  2004cited by this paper
• Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.

  2004cited by this paper
• Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.

  2003cited by this paper
• Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy

  2002cited by this paper
• TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension

  2002cited by this paper
• Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene

  2002cited by this paper
• Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy.

  2002cited by this paper
• Correlates of Left Atrial Size in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study

  2002cited by this paper
• Dyslipidemia and an Unfavorable Fatty Acid Profile Predict Left Ventricular Hypertrophy 20 Years Later

  2001cited by this paper
• Biochemical assessment of myocardial fibrosis in hypertensive heart disease.

  2001cited by this paper
• Regression of Left Ventricular Hypertrophy After Surgical Therapy for Aortic Stenosis Is Associated With Changes in Extracellular Matrix Gene Expression

  2001cited by this paper
• Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis

  2001cited by this paper
• Peripheral blood level alterations of TIMP‐1, MMP‐2 and MMP‐9 in patients with Type 1 diabetes

  2001cited by this paper
• Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.

  2001cited by this paper
• Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices

  2001cited by this paper
• Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study.

  2001cited by this paper
• Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.

  2000cited by this paper
• Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.

  2000cited by this paper
• Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

  1999cited by this paper
• Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.

  1999cited by this paper
• Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy

  1998cited by this paper
• Prediction of coronary heart disease using risk factor categories.

  1998cited by this paper
• Abnormalities of the extracellular degradation of collagen type I in essential hypertension.

  1998cited by this paper
• Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function.

  1998cited by this paper
• Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

  1998cited by this paper
• Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

  1998cited by this paper
• The Sleep Heart Health Study: design, rationale, and methods.

  1997cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction.

  1997cited by this paper
• Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum

  1992cited by this paper
• Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure.

  1992cited by this paper
• Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults.

  1988cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986cited by this paper
• An investigation of coronary heart disease in families. The Framingham offspring study.

  1979cited by this paper
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978cited by this paper
• The Life Study

  1973cited by this paper

• Not just a witness: Highlighting the utility of witness social defeat stress for the examination of neuroimmune-cardiovascular interactions across diverse populations

  2025cites this paper
• Niveles séricos de metaloproteinasas como biomarcadores predictivos de eventos cardiovasculares adversos en hombres con infarto con elevación del segmento ST

  2025cites this paper
• Assessment of Left Ventricular Strain Echocardiography in Individuals with Hashimoto’s Thyroiditis and Its Association with Serum TIMP-1 Concentration

  2025cites this paper
• Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature

  2025cites this paper
• Cold and hot fibrosis define clinically distinct cardiac pathologies

  2025cites this paper
• The TIMP Protein Family: Diverse Roles in Pathophysiology.

  2024cites this paper
• Inflammatory Markers Involved in the Pathogenesis of Dupuytren's Contracture.

  2024cites this paper
• Risk Factors Association with Transcriptional Activity of Metalloproteinase 9 (MMP-9) and Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) Genes in Patients with Heart Failure

  2024cites this paper
• Network-based prioritization and validation of regulators of vascular smooth muscle cell proliferation in disease

  2024cites this paper
• Transcriptional Activity of Metalloproteinase 9 (MMP-9) and Tissue Metalloproteinase 1 (TIMP-1) Genes as a Diagnostic and Prognostic Marker of Heart Failure Due to Ischemic Heart Disease

  2023cites this paper
• The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives

  2023cites this paper
• Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Framing Heartaches: The Cardiac ECM and the Effects of Age

  2023cites this paper
• Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson–Gilford Progeria Syndrome

  2023cites this paper
• Tissue Inhibitor of Metalloproteinases-1 Interacts with CD74 to Promote AKT Signaling, Monocyte Recruitment Responses, and Vascular Smooth Muscle Cell Proliferation

  2023cites this paper
• Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

  2022cites this paper
• TIMP-1: A Circulating Biomarker for Pulmonary Hypertension Diagnosis Among Chronic Obstructive Pulmonary Disease Patients

  2022cites this paper
• Coronary Artery Disease and Aortic Valve Stenosis: A Urine Proteomics Study

  2022cites this paper
• Onion and Apple Functional Ingredients Intake Improves Antioxidant and Inflammatory Status and Vascular Injury in Obese Zucker Rats

  2022cites this paper
• Simple Predictors for Cardiac Fibrosis in Patients with Type 2 Diabetes Mellitus: The Role of Circulating Biomarkers and Pulse Wave Velocity

  2022cites this paper
• Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

  2021cites this paper
• Evaluation of a multimarker panel in chronic heart failure: a 10-year follow-up.

  2021cites this paper
• A Potential Participant in Type 2 Diabetes Bone Fragility: TIMP-1 at Sites of Osteocyte Lacunar-Canalicular System

  2021cites this paper
• Predicting sulforaphane-induced adverse effects in colon cancer patients via in silico investigation.

  2021cites this paper
• Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

  2021cites this paper
• Assessment of the correlation between oxidative stress and expression of MMP-2, TIMP-1 and COX-2 in human aortic smooth muscle cells

  2021cites this paper
• Collagen Biosynthesis, Processing, and Maturation in Lung Ageing

  2021cites this paper
• Serum Matrix Metalloproteinases and Left Atrial Remodeling—The Hoorn Study

  2020cites this paper
• Serum tissue inhibitor of metalloproteinase‐1 and risk of cognitive impairment after acute ischaemic stroke

  2020cites this paper
• BIOMARKERS OF CARDIAC FIBROSIS IN ARTERIAL HYPERTENSION

  2020cites this paper
• The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel?

  2020cites this paper
• High-density lipoprotein-mediated cardioprotection in heart failure

  2020cites this paper
• Myocardial Basis for Heart Failure

  2020cites this paper
• The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients

  2020cites this paper
• Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II

  2020cites this paper
• Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population

  2020cites this paper
• Association of Circulating Tissue Inhibitor of Metalloproteinases‐1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease

  2019cites this paper
• Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial.

  2019cites this paper
• Tissue Inhibitor of Matrix Metalloproteinase 1 Increases With Ageing and Can Be Associated With Stroke　― Nested Case-Control Study ―

  2019cites this paper
• Mechanisms of cardiac collagen deposition in experimental models and human disease.

  2019cites this paper
• Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke

  2019cites this paper
• Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5 years cohort study

  2019cites this paper
• Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.

  2019cites this paper
• Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure

  2019cites this paper
• Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality

  2019cites this paper
• Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness.

  2019cites this paper
• Matrix Metalloproteinases and Their Tissue Inhibitors: an Evaluation of Novel Biomarkers in ANCA-Associated Vasculitis.

  2019cites this paper
• Fibrosis–Inflammation of the Cardiovascular System

  2019cites this paper
• Relationship of polymorphisms in the tissue inhibitor of metalloproteinase (TIMP)-1 and -2 genes with chronic heart failure

  2018cites this paper
• Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

  2018cites this paper
• Serum and saliva biomarkers in cardiovascular diseases and periodontitis: Smoking as a confounding factor

  2018cites this paper
• Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment

  2017cites this paper
• Physical versus psychological social stress in male rats reveals distinct cardiovascular, inflammatory and behavioral consequences

  2017cites this paper
• Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellitus.

  2017cites this paper
• Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63–Integrin &bgr;1 Interaction

  2017cites this paper
• Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

  2017cites this paper
• Metaloproteasas, remodelado vascular y síndromes

  2016cites this paper
• Heart failure due to right ventricular apical pacing: the importance of flow patterns.

  2016cites this paper
• Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy.

  2016cites this paper
• Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression.

  2015cites this paper
• Markers of fibrosis, inflammation, and remodeling pathways in heart failure.

  2015cites this paper
• Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition

  2015cites this paper
• The Long-Term Influence of Tissue Inhibitor of Matrix Metalloproteinase-1 in Patients with Mild to Moderate Coronary Artery Lesions in a Chinese Population: A 7-Year Follow-Up Study

  2015cites this paper
• Increased type I collagen synthesis in victims of sudden cardiac death due to idiopathic myocardial fibrosis

  2014cites this paper
• TIMP-1 polymorphisms in a Chinese Han population with intracerebral hemorrhage

  2014cites this paper
• β2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure

  2014cites this paper
• Association between mild myocardial injury post percutaneous coronary intervention and improvement of cardiac function through an increase in tissue inhibitor of

  2014cites this paper
• Stage B Heart Failure

  2014cites this paper
• Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

  2014cites this paper
• THE PROSPECTS OF STUDYING THE FEATURES OF VEGETATIVE REGULATION OF BLOOD CIRCULATION SYSTEM ACTIVITY IN THE PATIENTS WITH RHEUMATOID ARTHRITIS BY MEANS OF LASER DOPPLER FLOWMETRY

  2014cites this paper
• Matrix metalloproteinases in coronary artery disease.

  2014cites this paper
• Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases

  2014cites this paper
• Tissue Inhibitor of Matrix Metalloproteinases in the Pathogenesis of Heart Failure Syndromes

  2013cites this paper
• Circulating plasma serine208-phosphorylated troponin T levels are indicator of cardiac dysfunction

  2013cites this paper
• Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis

  2013cites this paper
• Risk factors in abdominal aortic aneurysm and in Polish population aortoiliac occlusive disease and differences between them

  2013cites this paper
• Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community‐based prospective cohort study

  2013cites this paper
• Evidence that periodontal treatment improves biomarkers and CVD outcomes.

  2013cites this paper
• Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli

  2013cites this paper
• ERRATUM: Risk factors in abdominal aortic aneurysm and aortoiliac occlusive disease and differences between them in the Polish population

  2013cites this paper
• New and Emerging Biomarkers in Left Ventricular Systolic Dysfunction—Insight into Dilated Cardiomyopathy

  2013cites this paper
• Insuffisance cardiaque : épidémiologie, caractéristiques des patients et de leur prise en charge, et facteurs pronostiques de décès

  2013cites this paper
• Evidence that periodontal treatment improves biomarkers and CVD outcomes.

  2013cites this paper
• Novel risk factors related to stable angina.

  2013cites this paper
• A infecção experimental pelo Trypanosoma cruzi agrava o desenvolvimento de lesões ateroscleróticas em camundongos apoE

  2012cites this paper
• Simultaneous up‐regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease

  2012cites this paper
• Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

  2012cites this paper
• Do we always consistently define the clinically important echocardiographic parameters?

  2012cites this paper
• Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.

  2012cites this paper
• Biomarkers.

  2012cites this paper
• Matrix metalloproteinases.

  2012cites this paper
• Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure.

  2012cites this paper
• Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans

  2012cites this paper
• Changes in the myocardial interstitium and contribution to the progression of heart failure.

  2012cites this paper
• Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort Study

  2011cites this paper
• Novel biomarkers in human terminal heart failure and under mechanical circulatory support

  2011cites this paper
• Multi-Analyte Profiling Reveals Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 as Plasma Biomarkers of Cardiac Aging

  2011cites this paper
• Identification of Systemic Markers from A Pulmonary Carbon Nanotube Exposure

  2011cites this paper
• Myocardial remodeling: cellular and extracellular events and targets.

  2011cites this paper
• Chapter 5 – Myocardial Basis for Heart Failure: Role of the Cardiac Interstitium

  2011cites this paper